Royal Bank of Canada’s Alnylam Pharmaceuticals ALNY Stock Holding History

Royal Bank of Canada’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-57,300	Closed	-$15.5M	–	6992
2025 Q1	$15.5M	Buy	+57,300	New	+$14.7M	﹤0.01%	1471
2024 Q2	–	Sell	-100	Closed	-$15K	–	6993
2024 Q1	$15K	Buy	+100	New	+$16.7K	﹤0.01%	6022
2021 Q1	–	Sell	-37,000	Closed	-$4.81M	–	7391
2020 Q4	$4.81M	Buy	+37,000	New	+$4.94M	﹤0.01%	2212
2017 Q1	–	Sell	-10,000	Closed	-$374K	–	6584
2016 Q4	$374K	Hold	10,000	–	–	﹤0.01%	4000
2016 Q3	$678K	Buy	+10,000	New	+$706K	﹤0.01%	3458
2013 Q3	–	Sell	-55,000	Closed	-$1.71M	–	6066
2013 Q2	$1.71M	Buy	+55,000	New	+$1.46M	﹤0.01%	2161

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royal Bank of Canada's ALNY Position: Q1 2026 in Review

Royal Bank of Canada increased its Alnylam Pharmaceuticals (ALNY) stake by 34% in Q1 2026, buying an estimated $68.1M and bringing the position to 791,515 shares worth $262M. The position accounts for 0.05% of the portfolio, ranked #346.

Royal Bank of Canada first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Royal Bank of Canada held 791,515 shares of Alnylam Pharmaceuticals worth $262M as of Q1 2026.
Royal Bank of Canada bought 200,020 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $68.1M.
Alnylam Pharmaceuticals made up 0.05% of Royal Bank of Canada's portfolio in Q1 2026, its #346 holding.
Royal Bank of Canada first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.